Introduction
============

In the modern era, percutaneous coronary intervention (PCI) with a drug-eluting stent has been used extensively for treatment of coronary artery disease, with dramatically reduced restenosis and target lesion revascularization rates[@b1-ppa-7-667],[@b2-ppa-7-667] when compared with the bare metal stent. Previous studies[@b3-ppa-7-667] have reported a gender-based difference in major adverse cardiac events (MACE) after index PCI procedures. However, comparative data concerning differences in clinical outcomes after drug-eluting stent implantation according to gender are still not available for the Chinese population. Therefore, the present study aimed to analyze the impact of gender on clinical outcomes after drug-eluting stent implantation in Chinese men and women.

Materials and methods
=====================

Patient population
------------------

Patients with acute myocardial infarction, unstable angina, stable angina, or silent ischemia who underwent PCI at our centers between January 2005 and December 2010 were prospectively registered. Patients with bare metal stent implantation were excluded from the analysis. In total, 3804 patients (2776 men, 1028 women) were recruited for this study.

PCI procedures
--------------

Coronary angiography and PCI with stent implantation were performed via the transfemoral or transradial approach. The decision to use intravascular ultrasound and selection of a sirolimus-eluting or paclitaxel-eluting stent was made by experienced interventional cardiologists. Angiographic success was defined as a residual stenosis ≤30% by visual estimation in the presence of grade 3 TIMI (Thrombolysis in Myocardial Infarction) flow. Procedural success was defined as achievement of angiographic success in the absence of inhospital events.

Definitions
-----------

The primary endpoint was a composite of MACE, including myocardial infarction, cardiac death, and target vessel revascularization, at two years. Stent thrombosis served as the safety endpoint. Diagnosis of myocardial infarction was based on American College of Cardiology/American Heart Association guidelines.[@b4-ppa-7-667],[@b5-ppa-7-667] Any unexplained death was diagnosed as being cardiac unless a noncardiac cause was identified. Target lesion revascularization was defined as repeat intervention on the stented segment, including the 5 mm proximal or distal to the stent. Target vessel revascularization was defined as repeat revascularization of the same vessel treated in the index procedure. Stent thrombosis was defined according to the Academic Research Consortium definition.[@b6-ppa-7-667] Definite stent thrombosis was defined as angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peristent region and at least one of the following additional criteria: symptoms of acute ischemia; ischemic changes on electrocardiography; and elevated cardiac enzymes. Probable stent thrombosis was defined as any unexplained death within 30 days of stent implantation, or any myocardial infarction related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.

Follow-up
---------

Patients were routinely followed up at one month, one year, and two years. Patients were followed up on an outpatient basis, by telephone contact, or via their relatives. The records for patients who visited other medical centers were also obtained. All clinical and imaging data were recorded in our database. Patients were advised to undergo repeat angiography once during the year following the procedure, but this was not done routinely for all patients. Earlier angiographic surveillance was performed if clinically indicated. Clinically driven target lesion or vessel revascularization was performed if there was at least 50% instent restenosis coupled with the presence of typical angina or exertional dyspnea of new onset.

Medications
-----------

All patients were pretreated with 300 mg of both aspirin and clopidogrel. Patients were maintained on aspirin 100 mg and clopidogrel 100 mg once daily. All patients were recommended to take aspirin 100 mg daily lifelong. Clopidogrel 75 mg per day was prescribed for at least 12 months, according to the clinical guidelines at that time.

Statistical analysis
--------------------

The Kolmogorov--Smirnov test was used to assess the distribution of continuous variables. Continuous variables were expressed as the mean ± standard deviation or median, and were compared using the Student's *t*-test (for normal data) and the Mann--Whitney *U* test (for non-normally distributed variables) as appropriate. Categorical variables are presented as frequencies or percentages, which were compared by chi-square or Fisher's exact test. Survival curves were generated using the Kaplan--Meier method, and were compared using the log-rank test. A propensity score analysis was performed to minimize any selection bias arising from differences in baseline characteristics according to gender. Variables included in the logistic regression model to calculate the propensity score were age, gender, body mass index, hypertension, diabetes, hyperlipidemia, acute myocardial infarction, chronic renal insufficiency, left ventricular ejection fraction, multivessel disease, left main stem coronary artery disease, thrombus-containing lesion, chronic total occlusion, transradial approach, incomplete revascularization, type of stent, post-stenting TIMI grade, number of stents, stent diameter, stent length, procedural time, and contrast volume. The C statistic was 0.67 and the Hosmer--Lemeshow *P* value was 0.114, confirming good discrimination and calibration of the propensity score model. The new propensity score was then incorporated into Cox proportional hazards regression models as a covariate to assess the clinic outcome for women versus men. In addition, to reduce the effect of treatment selection bias and potential confounding in this observational study, we performed rigorous adjustment for significant differences in the baseline characteristics of patients, with propensity score matching using the following algorithm: a 1:1 optimal match with a ± 0.03 caliper and no replacement. Clinical outcomes in the matched population were analyzed with Cox proportional hazards regression stratified on matched pairs. Multivariable Cox proportional hazards regression modeling was performed to identify independent predictors of the primary endpoint (MACE, including cardiac death, myocardial infarction, target lesion or vessel revascularization) with purposeful selection of covariates. Variables associated at univariate analysis (all *P* values ≤0.1) and those judged to be of clinical importance from previous published reports were eligible for inclusion in the multivariable model building process. The goodness of fit of the Cox multivariable model was assessed using the Grønnesby--Borgan--May test. Results are reported as the hazards ratio with the 95% confidence interval and *P* value. All statistical analysis was performed using Stata version 12.0 software (Stata Corporation, College Station, TX, USA).

Results
=======

Baseline clinical characteristics
---------------------------------

Of the 3804 patients, 2776 were men and 1028 were women. Baseline characteristics are shown in [Table 1](#t1-ppa-7-667){ref-type="table"}. Women were characterized by older age, lower height/weight, higher blood pressure, fasting blood glucose, and interleukin-6 levels, more frequent dyslipidemia, renal dysfunction, use of calcium channel blockers, and angiotensin receptor blockers, and well preserved left ventricular function. In contrast, male patients were found to have a significantly greater incidence of ST elevation myocardial infarction (STEMI) compared with women (*P* \< 0.001).

Angiographic and procedural features
------------------------------------

The angiographic and procedural features of the patients are shown in [Table 2](#t2-ppa-7-667){ref-type="table"}. Men appeared to have more frequent complex lesions. Left main stem lesions (12.5% in males versus 9.7% in females, *P* = 0.017), bifurcations (34.1% versus 30%, *P* = 0.016), and thrombus-containing lesions (13.1% versus 6.1%, *P* ≤ 0.001), resulting in more stents being needed (1.99 ± 1.08 versus 1.85 ± 1.01, *P* \< 0.001) and a longer procedural time (49.48 ± 28.45 versus 45.67 ± 24.42, *P* \< 0.001), higher contrast volume (211.17 ± 78.80 versus 201.98 ± 57.98, *P* \< 0.001), and less complete revascularization (59.7% versus 66.3%, *P* ≤ 0.001). There was also a difference in the percentage of transradial approaches used between men and women (60.7% versus 55.9%, respectively, *P* = 0.008), with a difference in stent diameter (3.13 ± 0.44 versus 3.08 ± 045, *P* = 0.003) and stent length (52.36 ± 31.72 versus 47.40 ± 30.68, *P* \< 0.001) between the genders.

Cumulative MACE during one year of follow-up
--------------------------------------------

Nearly 94.7% of patients underwent repeat angiography during one year of follow-up ([Table 3](#t3-ppa-7-667){ref-type="table"}). The rate of inhospital myocardial infarction was higher in men at 6.3%, mainly because of an increment in the rate of non-STEMI (4.5%), compared with women (3.3% and 1.9%, respectively, both *P* \< 0.001). The composite inhospital rate for MACE was significantly different between women and men (5.2% versus 7.5%, *P* = 0.011).

Cumulative MACE during two years of follow-up
---------------------------------------------

At two years after the index PCI procedure ([Table 4](#t4-ppa-7-667){ref-type="table"}), unadjusted rates of myocardial infarction, non-STEMI, target vessel revascularization, and MACE were significantly different between men (6.84%, 4.6%, 13.1%, and 21.7%) and women (3.8% \[*P* = 0.001\], 2.0% \[*P* \< 0.001\] 10.3% \[*P* = 0.025\], and 16.3% \[*P* \< 0.001\], respectively). Other clinical outcomes, including death, target lesion revascularization, coronary artery bypass grafting, and stent thrombosis (including definite, probable, possible, late, or very late), were similar between men and women.

After propensity score matching, 365 pairs of men and women were identified ([Table 5](#t5-ppa-7-667){ref-type="table"}). There were no significant differences in individual endpoints (myocardial infarction, STEMI, non-STEMI, death, target lesion or vessel revascularization, coronary artery bypass grafting) or composite MACE between men and women. Stent thrombosis was 1.4% in women versus 0.8% in men (*P* = 0.484). Cox multivariable analysis demonstrated that myocardial infarction (hazards ratio 1.63, 95% confidence interval 1.21--2.18, *P* = 0.001) was the only independent risk factor for the composite of MACE ([Figure 1](#f1-ppa-7-667){ref-type="fig"}).

Discussion
==========

The present study yielded several major findings. First, there was an obvious discrepancy in baseline clinical and lesional characteristics between Chinese women and men, and second, male patients had higher unadjusted rates of myocardial infarction, non-STEMI, target vessel revascularization, and MACE. However, this difference between men and women became narrow after propensity matching score.

Previous studies have shown that women have more risk factors and are older than men at the time of presentation with acute coronary syndrome.[@b7-ppa-7-667],[@b8-ppa-7-667] This discrepancy is consistent with the delayed onset of coronary artery disease in women, in whom estrogen is thought to have a cardioprotective effect.[@b9-ppa-7-667] In the current Chinese analysis,female patients had similar risk factors and were older than male patients. Several previous studies[@b10-ppa-7-667]--[@b14-ppa-7-667] have reported poor outcomes and a higher incidence of MACE after PCI in women with diabetes mellitus, although a study by Ogita et al[@b15-ppa-7-667] showed no significance difference between the genders after elective drug-eluting stent implantation in diabetic patients. As in our study, diabetes mellitus did not emerge as an independent predictor of MACE in women after implantation of a drug-eluting stent. This can be explained by the fact that previous studies did not report the type of stent used and did not perform propensity score matching. The SYNERGY (Superior Yield of the New strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors) trial[@b16-ppa-7-667] concluded that chronic kidney disease (derived from the estimated glomerular filtration rate) was predictive of 30-day mortality, myocardial infarction, and bleeding, which is in contrast with our finding that, although women had a higher rate of renal insufficiency compared with men, the unadjusted myocardial infarction rate was higher in men than in women. This is in line with the results of a study by Kralev et al,[@b17-ppa-7-667] who reported that female gender did not emerge as an independent predictor of MACE despite the worse baseline clinical features seen in women. Several studies[@b18-ppa-7-667],[@b19-ppa-7-667] have indicated no difference in clinical outcome between men and women after invasive treatment. Further, Schuhlen et al[@b20-ppa-7-667] found that female gender conferred no excess risk for MACE after PCI. Lansky et al[@b21-ppa-7-667] concluded that despite having more comorbid risk factors than men, women were likely to have less extensive coronary artery disease by both angiographic and intravascular ultrasound measures; however, they found no significant difference in MACE at three years between men and women. Consistent with a previous study,[@b21-ppa-7-667] we found different lesional characteristics between men and women, and reporting of the adjusted rate for baseline clinical and lesional characteristics would be helpful. As already mentioned by Lansky et al,[@b22-ppa-7-667] women tend to have increased inhospital mortality after both elective and primary PCI compared with men, but this difference becomes smaller after adjustment for women's older age, smaller body surface area, and comorbidities at presentation. We also found that this difference between men and women diminished after using propensity matching. In previous research, lack of use of a propensity score was often a source of bias with regard to baseline clinical and lesional characteristics appearing to be dissimilar between men and women. In our study, women had more clinical risk factors, but men had more specific lesions. Therefore, propensity score matching reflects the interplay between baseline clinical and lesional characteristics.

In our study, men had more extensive coronary lesions, so were likely to have longer stents and to undergo a greater number of stenting procedures. The increase in stent number and length is mainly attributable to increased target lesion revascularization and instent restenosis causing myocardial infarction and an increase in MACE.[@b23-ppa-7-667],[@b24-ppa-7-667] The outcome of unadjusted MACE with target vessel revascularization at two-year follow-up explains the discontinuation of dual antiplatelet therapy, and Brener et al[@b25-ppa-7-667] suggested that prolonged dual antiplatelet therapy reduces MACE after PCI. A previous study by Harmsze et al[@b26-ppa-7-667] concluded that many patients are resistant to the idea of anticoagulant medication, which can be a major cause of MACE after PCI. Like the work reported by Nguyen et al,[@b27-ppa-7-667] our study contained more men than women, potentially reflecting a degree of gender bias when referring patients for coronary angiography. Certain clinical features, such as severity of disease, flow reserve, local inflammation, or lesion complexity might be surrogates for predicting outcomes. For example, the degree of intimal hyperplasia is significantly greater in lesions treated with longer stents.[@b28-ppa-7-667]

Conclusion
==========

Although baseline clinical variables differed between women and men in this study, and women had less extensive coronary lesions than men, both genders had similar outcomes after drug-eluting stent implantation in this Chinese population. Our present study suffers from the limitations of any nonrandomized trial. The significant difference between the genders in terms of baseline demographics and the smaller number of women included could have led to bias in interpretation of the study results. Another limitation of this study was the use of medium-term clinical outcomes, which could account for the lack of a significant difference seen in outcomes after propensity score matching between men and women. Further, we did not investigate for differences in clinical outcome between the types of stent used. We also did not compare images obtained on intravascular ultrasound for men and women. Future research on the outcomes of drug-eluting stent implantation should investigate intravascular ultrasound or fractional flow reserve in men and women, enabling translation of the results into real-world practice.
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###### 

Baseline clinical characteristics

                                            Women (n = 1028)   Men (n = 2776)   *P* value
  ----------------------------------------- ------------------ ---------------- -----------
  Age, years                                66.17 ± 9.10       63.76 ± 10.56    \<0.001
  Height (cm)                               159.14 ± 5.10      169.31 ± 4.97    \<0.001
  Weight (kg)                               62.30 ± 9.22       70.75 ± 9.75     \<0.001
  Body mass index, kg/m^2^                  24.58 ± 3.41       24.64 ± 2.96     0.634
  Hypertension, n (%)                       787 (76.6)         1903 (68.6)      \<0.001
   Systolic BP                              136.60 ± 20.14     133.76 ± 20.23   \<0.001
   Diastolic BP                             79.66 ± 11.15      80.67 ± 12.31    0.017
  Hyperlipidemia, n (%)                     411 (40.0)         921 (33.2)       \<0.001
   Fasting total cholesterol, mmol/L        4.57 ± 0.87        4.30 ± 0.83      \<0.001
   Fasting LDL, mmol/L                      2.94 ± 0.78        2.75 ± 0.75      \<0.001
   Fasting HDL, mmol/L                      1.0 ± 0.08         0.99 ± 0.08      \<0.001
   Fasting triglycerides, mmol/L            1.56 ± 0.24        1.57 ± 0.37      0.461
  Diabetes, n (%)                           356 (34.6)         796 (28.7)       \<0.001
   Fasting glucose, mmol/L                  6.78 ± 2.06        6.72 ± 2.06      0.416
   Insulin                                  96 (27.0)          196 (24.6)       0.420
   Oral antiglycemics                       248 (69.7)         533 (67.0)       0.376
  Chronic renal insufficiency, n (%)        129 (12.5)         266 (9.6)        0.008
   Estimated GFR, mL/min/1.73 m^2^          67.73 ± 14.95      69.96 ± 20.46    0.001
  Presentation, n (%)                                                           \<0.001
   Stable angina                            168 (16.3)         365 (13.1)       0.013
   Unstable angina                          661 (64.3)         1523 (54.9)      \<0.001
   STEMI                                    140 (13.6)         685 (24.7)       \<0.001
   Non-STEMI                                59 (5.7)           203 (7.3)        0.097
  Congestive heart failure, n (%)           223 (21.7)         562 (20.2)       0.343
  Left ventricular ejection fraction, %     59.34 ± 7.84       57.91 ± 8.42     \<0.001
  Interleukin 6                             9.83 ± 1.77        9.74 ± 1.96      0.030
  Highly sensitive C-reactive protein       26.62 ± 4.67       27.46 ± 4.57     0.550
  Medication, n (%)                                                             
   Statins                                  138 (13.4)         374 (13.5)       1.0
   Beta-blockers                            173 (16.8)         397 (14.3)       0.058
   Diuretics                                68 (6.6)           146 (5.3)        0.113
   Calcium channel blockers                 340 (33.1)         767 (27.6)       0.001
   Angiotensin-converting enzyme blockers   131 (12.7)         399 (14.4)       0.206
   Angiotensin receptor blockers            107 (10.4)         228 (8.2)        0.039

**Abbreviations:** BP, blood pressure; GFR, glomerular filtration rate; STEMI, ST-segment elevation myocardial infarction; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol.

###### 

Angiographic and procedural features

                                      Women (n = 1028)   Men (n = 2776)   *P* value
  ----------------------------------- ------------------ ---------------- -----------
  Diseased vessels (n)                1.30 ± 0.56        1.33 ± 0.57      0.223
   One                                770 (74.9)         2011 (72.4)      0.138
   Two                                199 (19.4)         601 (21.6)       0.128
   Three                              59 (5.7)           164 (5.9)        0.877
  Distribution of lesions (n, %)                                          
   LAD                                684 (66.5)         1788 (64.4)      0.235
   LCX                                247 (24.0)         668 (24.1)       1.0
   RCA                                309 (30.1)         895 (32.2)       0.209
   LM                                 100 (9.7)          348 (12.5)       0.017
  CTO lesion                          5 (0.5)            12 (0.4)         0.788
  Distribution                                                            0.520
   LAD                                4 (0.3)            10 (0.3)         
   LCX                                1 (0.1)            1 (0.03)         
   RCA                                2 (0.2)            3 (0.1)          
   \>1 CTO                            1 (0.1)            2 (0.07)         1.0
  Bifurcating lesions (n, %)          308 (30.0)         947 (34.1)       0.016
  Thrombus-containing                 63 (6.1)           364 (13.1)       \<0.001
  Transradial approach (n, %)         575 (55.9)         1685 (60.7)      0.008
  Sirolimus-eluting stent             879 (85.5)         2388 (86.0)      0.714
  Complete revascularization (n, %)   682 (66.3)         1656 (59.7)      \<0.001
  Post-stenting TIMI grade (n, %)                                         0.655
   0                                  11 (1.1)           37 (1.3)         
   1                                  0                  4 (0.1)          
   2                                  8 (0.8)            17 (0.6)         
   3                                  1009 (98.2)        2718 (97.9)      
  Stents (n)                          1.85 ± 1.01        1.99 ± 1.08      \<0.001
  BP-SES (n, %)                       350 (34.0)         1037 (37.4)      0.060
  Stent diameter (mm)                 3.08 ± 0.45        3.13 ± 0.44      0.003
  Stent length (mm)                   47.40 ± 30.68      52.36 ± 31.72    \<0.001
  Post-dilation                       948 (92.2)         2540 (91.5)      0.475
  Procedural time (minutes)           45.67 ± 24.42      49.48 ± 28.45    \<0.001
  Contrast volume (mL)                201.98 ± 57.98     211.17 ± 78.80   \<0.001

**Abbreviations:** CTO, chronic total occlusion; LAD, left anterior descending artery; LCX, left circumflex artery; LM, left main; MV, main vessel; RCA, right coronary artery; BP-SES, biodegradable polymer sirolimus-eluting stents; TIMI, Thrombolysis in Myocardial infarction.

###### 

Cumulative major adverse cardiac events during one year of follow-up

                                 Women (n = 1028)   Men (n = 2776)   *P* value
  ------------------------------ ------------------ ---------------- -----------
  Repeat angiography (n, %)      973 (94.6)         2634 (94.9)      0.805
  Days from PCI to angiography   244 (81)           244 (69)         0.154
  Inhospital, n (%)                                                  
   MI                            34 (3.3)           175 (6.3)        \<0.001
   STEMI                         14 (1.4)           51 (1.8)         0.330
   Non-STEMI                     20 (1.9)           124 (4.5)        \<0.001
   Death                         22 (2.1)           40 (1.4)         0.149
    Cardiac                      20 (1.9)           38 (1.4)         0.232
   TLR                           5 (0.5)            16 (0.6)         0.812
   CABG                          3 (0.3)            7 (0.3)          0.735
   TVR                           9 (0.9)            25 (0.9)         1.0
   MACE                          53 (5.2)           208 (7.5)        0.011
   Stent thrombosis              4 (0.4)            18 (0.6)         0.472
    Definite                     3 (0.3)            14 (0.5)         0.584
  Probable                       1 (0.1)            4 (0.1)          1.0
  At one month, n (%)                                                
   MI                            33 (3.2)           175 (6.3)        \<0.001
  STEMI                          13 (1.3)           51 (1.8)         0.257
  Non-STEMI                      20 (1.9)           124 (4.5)        \<0.001
   Death                         28 (2.7)           66 (2.4)         0.557
    Cardiac                      23 (2.2)           61 (2.2)         1.0
   TLR                           5 (0.5)            18 (0.6)         0.646
   CABG                          3 (0.3)            8 (0.3)          1.0
   TVR                           9 (0.9)            28 (1.0)         0.853
   MACE                          55 (5.4)           223 (8.0)        0.005
   Stent thrombosis              7 (0.7)            24 (0.9)         0.687
    Definite                     3 (0.3)            15 (0.5)         0.430
  Probable                       4 (0.4)            9 (0.3)          0.758
  At one year, n (%)                                                 
   MI                            39 (3.8)           184 (6.6)        0.001
    STEMI                        18 (1.8)           57 (2.1)         0.602
    Non-STEMI                    21 (2.0)           127 (4.6)        \<0.001
   Death                         55 (5.4)           141 (5.1)        0.741
    Cardiac                      38 (3.7)           99 (3.6)         0.922
   TLR                           72 (7.0)           230 (8.3)        0.200
   CABG                          6 (0.6)            17 (0.6)         1.0
   TVR                           94 (9.1)           315 (11.3)       0.052
   MACE                          152 (14.8)         550 (19.8)       \<0.001
   Stent thrombosis              8 (0.8)            32 (1.2)         0.374
    Definite                     3 (0.3)            15 (0.5)         0.430
  Probable                       4 (0.4)            9 (0.3)          0.758
  Possible                       1 (0.1)            8 (0.3)          0.459
    Late                         2 (0.2)            8 (0.3)          1.0

**Abbreviations:** CABG, coronary artery bypass graft; MACE, major adverse cardiac events; STEMI, ST-segment elevation myocardial infarction; TLR, target lesion revascularization; TVR, target vessel revascularization; MI, myocardial infarction; PCI percutaneous coronary intervention.

###### 

Cumulative major adverse cardiac events during two years of follow-up

                                      Women (n = 1028)   Men (n = 2776)   Hazards ratio       *P* value
  ----------------------------------- ------------------ ---------------- ------------------- -----------
  At two years, n (%)                                                                         
   MI                                 39 (3.8)           190 (6.84)       0.55 (0.39--0.78)   0.001
    STEMI                             18 (1.8)           61 (2.2)         0.79 (0.47--1.33)   0.371
    Non-STEMI                         21 (2.0)           129 (4.6)        0.44 (0.28--0.69)   \<0.001
   Death                              67 (6.5)           179 (6.4)        1.01 (0.77--1.34)   0.927
    Cardiac                           42 (4.1)           109 (3.9)        1.04 (0.73--1.49)   0.816
   TLR                                82 (8.0)           266 (9.6)        0.83 (0.65--1.06)   0.139
   CABG                               6 (0.6)            19 (0.7)         0.85 (0.34--2.14)   0.737
   TVR                                106 (10.3)         363 (13.1)       0.78 (0.63--0.97)   0.025
   MACE                               168 (16.3)         604 (21.7)       0.73 (0.61--0.86)   \<0.001
   Stent thrombosis                   9 (0.9)            33 (1.2)         0.74 (0.35--1.54)   0.415
    Definite                          3 (0.3)            15 (0.5)         0.54 (0.16--1.87)   0.330
  Probable                            4 (0.4)            2 (0.4)          1.20 (0.37--3.90)   0.761
  Possible                            2 (0.2)            9 (0.3)          0.60 (0.13--2.77)   0.511
    Late or very late                 3 (0.3)            9 (0.3)          0.90 (0.24--3.31)   0.871
  After propensity score matching\*                                                           
   MI                                 24 (6.6)           22 (6.0)         1.1 (0.60--2.02)    0.758
    STEMI                             9 (2.5)            8 (2.2)          1.13 (0.43--2.92)   0.808
    Non-STEMI                         15 (4.1)           14 (3.8)         1.08 (0.51--2.29)   0.847
   Death                              23 (6.3)           24 (6.6)         0.95 (0.52--1.76)   0.876
    Cardiac                           16 (4.4)           17 (4.7)         0.93 (0.45--1.93)   0.853
   TLR                                24 (6.6)           30 (8.2)         0.79 (0.45--1.37)   0.397
   CABG                               0                  2 (0.6)                              0.499
   TVR                                33 (9.0)           43 (11.8)        0.74 (0.46--1.20)   0.227
   MACE                               61 (16.7)          75 (20.6)        0.77 (0.53--1.12)   0.183
   Stent thrombosis                   5 (1.4)            3 (0.8)          1.67 (0.40--6.97)   0.484
    Definite                          2 (0.6)            1 (0.3)          0.20 (0.18--22.6)   0.571
  Probable                            2 (0.6)            2 (0.6)          1.0 (0.14--7.10)    1.0
    Late or very late                 1 (0.3)            0                                    1.0

**Note:** \*n = 365 in both women and men.

**Abbreviations:** CABG, coronary artery bypass graft; MACE, major adverse cardiac events; STEMI, ST-segment elevation myocardial infarction; TLR, target lesion revascularization; TVR, target vessel revascularization; MI, myocardial infarction.

###### 

Predictors of primary endpoints, ie, major adverse cardiac events, at Cox multivariate analysis

  Predictors                    HR     95% CI       *P* value
  ----------------------------- ------ ------------ -----------
  Women versus men              0.76   0.58--1.01   0.058
  Acute myocardial infarction   1.63   1.21--2.18   0.001
  Transradial approach          0.74   0.58--0.95   0.001
  Sirolimus-eluting stent       0.62   0.42--0.91   0.015
  Complete revascularization    0.77   0.60--0.99   0.042
  Stent diameter                0.53   0.37--0.71   \<0.001

**Abbreviations:** CI, confidence interval; HR, hazards ratio.
